MLH1 and mismatch repair cancer syndrome 1: All studies mention at least sporadic testing for BRAF V600E or MLH1 promoter hypermethylation in tumors showing MLH1/PMS2 loss, recognizing the significance of these markers in distinguishing sporadic from inherited MMR deficiency.